Last reviewed · How we verify

NCT04982341

HFNC and Prone Positioning in Awake Patients With Severe COVID-19

Completed Last updated 29 July 2021
What this trial tests

trial testing prone position in Hypoxemic Respiratory Failure in 120 participants. Completed in 3 March 2021.

Timeline
2 September 2020
Primary endpoint
3 March 2021
3 March 2021

Quick facts

Lead sponsorHôpital Universitaire Fattouma Bourguiba
StatusCompleted
Study typeOBSERVATIONAL
Enrollment120
Start date2 September 2020
Primary completion3 March 2021
Estimated completion3 March 2021
Sites1 location across Tunisia

Drugs / interventions tested

Conditions studied

Sponsor

Hôpital Universitaire Fattouma Bourguiba

Who can join

Eligibility, any sex, with Hypoxemic Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators evaluate the effects of High-flow nasal cannula (HFNC) in association with prone in patients with Covid-19 severe ARF.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of prone position

Trials testing the same drug.

Other recruiting trials for Hypoxemic Respiratory Failure

Currently open trials in the same condition.

Other Hôpital Universitaire Fattouma Bourguiba trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04982341.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing